Wednesday, April 23, 2014 |
08:30 AM - 10:30 AM Eastern Daylight Time |
On March 12, the California Supreme Court denied review of a $407 million judgment, which included approximately $360 million in lost-profit damages, arising from Swiss drugmaker Actelion Ltd.’s acquisition of California biotech startup CoTherix, Inc.
Some observers have predicted that the published appellate court opinion affirming the judgment will cause a wave in lost-profit litigation, push pharmaceutical firms out California, and discourage companies from participating in mergers and acquisitions, ultimately hampering California’s notorious start-up culture. In this seminar, the Asahi trial and appellate team will address these concerns and cover the following three topics of interest arising from the litigation: